People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| bluebird bio, Inc. | — | Biotechnology | Series C | $187.5M | $1.9B | 2010 |
| KALA BIO, Inc. | — | Biotechnology | Series C | $158.8M | $8.3M | 2010 |
| Foundation Medicine, Inc. | — | Biotechnology | Series C | $115.5M | $2.3B | 2010 |
| Neon Therapeutics, Inc. | — | Biotechnology | Series D+ | $106.0M | $4.4B | 2016 |
| Dare Bioscience, Inc. | — | Biotechnology | Series B | $102.0M | $93.7M | 2009 |
| Allena Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $80.5M | $75.0M | 2014 |
| Faze Medicines, Inc. | — | Biotechnology | Series B | $30.4M | $998.4M | 2020 |
Robert Tepper at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Tepper on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 2 | 36 |
| Steven Gillis | 1 | 23 |
| Kevin Bitterman | 1 | 15 |
| James Topper | 1 | 12 |
| John P Ryan | 1 | 11 |
| Alan Crane | 1 | 9 |
| Mark Levin | 1 | 9 |
| Terry McGuire | 1 | 8 |
| Stephen Kraus | 1 | 7 |
| Bryan E. Roberts | 1 | 6 |
| Axel Bolte | 1 | 6 |
| Alexis Borisy | 1 | 6 |
| Daniel S. Lynch | 1 | 6 |
| Nick Leschly | 1 | 5 |
| Gino Santini | 1 | 5 |
| DAVID LAZAR | 1 | 5 |
| Steven E. Hall | 1 | 4 |
| Cheryl R. Blanchard | 1 | 4 |
| Cary Pfeffer | 1 | 4 |
| Howard B. Rosen | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.